This article reviews the primary goals and achievements of the Italian Association for Pediatric Hematology-Oncology (Associazione Italiana Ematologia Oncologia Pediatrica [AIEOP]), a national cooperative group that has been working for children and adolescents with cancer in Italy since 1975.
ZucchettiGBertorelloNAngelastroA, et al. Improving healthcare in pediatric oncology: development and testing of multiple indicators to evaluate a hub-and-spoke model. Tumori2018; 104: 459–465.
2.
DamaERondelliRDe RosaM, et al. Patterns of domestic migrations and access to childhood cancer care centres in Italy: a report from the hospital-based registry of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Eur J Cancer2008; 44: 2101–2105.
3.
ConterVAricòMBassoG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia2010; 24: 255–264.
4.
ConterVBartramCRValsecchiMG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood2010; 115: 3206–3214.
5.
PessionAMasettiRRizzariC, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood2013; 122: 170–178.
6.
LocatelliFBernardoMEBertainaA, et al. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol2017; 18: 1126–1136.
7.
De BernardiBNicolasBBoniL, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-operative Group for Neuroblastoma. J Clin Oncol2003; 21:1592–1601.
8.
SpreaficoFGandolaLD’AngeloP, et al. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Int J Radiat Oncol Biol Phys2012; 82: 348–354.
9.
LukschRTienghiAHallKS, et al. Primary metastatic Ewing’s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol2012; 23: 2970–2976.
10.
MassiminoMMiceliRGiangasperoF, et al. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro-Oncol2016; 18: 1451–1460.
11.
BisognoGDe SalvoGLBergeronC, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol2019; 20: 1566–1575.
12.
PessionARondelliR.Collection and transfer of data: the AIEOP model. Bone Marrow Transpl2008; 41(Suppl 2): S35–S38.
13.
PessionADamaERondelliR, et al. Survival of children with cancer in Italy, 1989-98: a report from the hospital-based registry of the Italian Association of Paediatric Haematology and Oncology (AIEOP). Eur J Cancer2008; 44: 1282–1289.
14.
FerrariAQuarelloPMascarinM, et al. Evolving services for adolescents with cancer in Italy: access to pediatric oncology centers and dedicated projects. J Adolesc Young Adult Oncol2020; 9: 196–201.
15.
FerrariABarrRD.International evolution in AYA oncology: current status and future expectations. Pediatr Blood Cancer2017; 64.
16.
FerrariA.The challenge of access to care for adolescents with cancer in Italy: national and local pediatric oncology programs: international perspectives on AYAO, part 2. J Adolesc Young Adult Oncol2013; 2: 112–117.
17.
FerrariADamaEPessionA, et al. Adolescents with cancer in Italy: entry into the national cooperative pediatric oncology group AIEOP trials. Eur J Cancer2009; 45: 328–334.
18.
FerrariARondelliRPessionA, et al. Adolescents with cancer in Italy: improving access to national cooperative pediatric oncology group (AIEOP) centers. Pediatr Blood Cancer2016; 63: 1116–1119.
19.
HauptREssiafSDellacasaC, et al. The ‘Survivorship Passport’ for childhood cancer survivors. Eur J Cancer2018; 102: 69e81.
20.
GeenenMMCardous-UbbinkMCKremerLC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA2007; 297: 2705–2715.
21.
SpreaficoFQuarelloPAlaggioR, et al. Nationwide central diagnosis review for childhood solid tumors: from concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project. Pediatr Blood Cancer2019; 66: e27749.
22.
TeotLASpostoRKhayatA, et al; Children’s Oncology Group. The problems and promise of central pathology review: development of a standardized procedure for the Children’s Oncology Group. Pediatr Dev Pathol2007; 10: 199–207.
23.
Lopez-BeltranACanas-MarquesRChengL, et al. Histopathologic challenges: the second opinion issue. Eur J Surg Oncol2019; 45: 12–15.
24.
BassoGVeltroniMValsecchiMG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol2009; 27(31): 5168–5174.
25.
MagniCSegrèCFinziC, et al. Adolescents’ health awareness and understanding of cancer and tumor prevention: when and why an adolescent decides to consult a physician. Pediatr Blood Cancer2016; 63: 1357–1361.
